Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794726 | 0.77 | MYC (0.41) | MYCALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL27504693 | 0.72 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL31668450 | 0.72 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL28208533 | 0.69 | POLB (0.48) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL1075595 | 0.69 | POLB (0.48) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL16009974 | 0.69 | POLB (0.48) | MYCALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL30344008 | 0.69 | POLB (0.64) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL1180653 | 0.69 | POLB (0.64) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL996292 | 0.67 | ABCB1 (0.50) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL23854172 | 0.66 | POLB (0.44) | ALDH1A1KDM4EMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080120-B1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-06-19 | — | — | EP | disclosed |
| US-10004737-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BY) | 2018-06-26 | — | — | US | disclosed |
| US-20170128445-A1 | Fused Imidazole and Pyrazole Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | disclosed |
| EP-3080120-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086512-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004737-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | MYC 3217/4885ALDH1A1 1594/4885KDM4E 4258/4885 |
| US-20170128445-A1 | Fused Imidazole and Pyrazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | MYC 3230/4885ALDH1A1 1651/4885KDM4E 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.